Idogen has successfully established a novel method for the company's cell therapy
Idogen AB ("Idogen") announces today that the company has successfully established a novel method for the preparation of their tolerogenic cell therapy. In January 2019 an evaluation of a number of new potential methods in an improved analysis model was initiated, which makes it possible to assess the tolerogenic effect on human immune cells in the laboratory with improved precision. This extensive work has now been completed with very good results. Idogen's tolerogenic cell therapy is based on dendritic cells, a type of white blood cells that plays a central role in the immune defence